PD-008 Adding ramucirumab to second-line irinotecan, 5-fluorouracil and folinic acid (FOLFIRI) treatment for metastatic colorectal carcinoma (mCRC): resource utilization data from RAISE, a global, randomized, double-blind, multicenter phase 3 study
Titel:
PD-008 Adding ramucirumab to second-line irinotecan, 5-fluorouracil and folinic acid (FOLFIRI) treatment for metastatic colorectal carcinoma (mCRC): resource utilization data from RAISE, a global, randomized, double-blind, multicenter phase 3 study
Auteur:
Kisro, J. Cohn, A. Yoshino, T. Van Cutsem, E. Hegewisch-Becker, S. Kullmann, F. Brück, P. Liepa, A. Yang, L. Nasroulah, F. Tabernero, J.